DaVita (NYSE:DVA) Posts Earnings Results, Beats Estimates By $0.14 EPS

Posted by Stanley Muller on Aug 4th, 2026

DaVita (NYSE:DVA – Get Free Report) posted its quarterly earnings data on Tuesday. The company reported $4.02 EPS for the quarter, beating analysts’ consensus estimates of $3.88 by $0.14, FiscalAI reports. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. The business had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.50 billion. DaVita updated its FY 2026 guidance to 14.100-15.200 EPS.

Here are the key takeaways from DaVita’s conference call:

DaVita reaffirmed its 2026 guidance, including adjusted operating income of $2.2 billion at the midpoint and adjusted EPS of $14.65. Management expects fourth-quarter adjusted operating income to exceed third-quarter results by $50 million to $100 million, primarily due to IKC timing.
Treatment-volume growth accelerated, supported by sustained improvements in patient mortality. DaVita now expects 2026 treatment growth near the top of its prior 25–50 basis-point range, or roughly 50–75 basis points after normalizing for calendar effects.
DaVita plans to broadly deploy expanded hemodialysis using Nipro’s newly approved medium cut-off dialyzer in the coming quarters. The technology is compatible with existing machines, supply has been secured, and management believes any meaningful financial upside from lower mortality would begin around 2028.
Revenue per treatment declined sequentially because of lower commercial insurance mix following the expiration of ACA subsidies and reduced phosphate-binder revenue. Management continues to estimate a roughly $40 million 2026 headwind from commercial-mix changes, potentially increasing to $70 million in 2027.
The transition of phosphate binders into the Medicare bundle has reduced reliance on less-effective over-the-counter treatments by more than 50%, while lowering DaVita’s related revenue and costs. Management supports the policy and expects the final 2027 ESRD payment rule to determine the ultimate financial impact.

DaVita Trading Down 2.4%

Shares of DVA traded down $5.51 during midday trading on Tuesday, hitting $228.17. The stock had a trading volume of 2,604,633 shares, compared to its average volume of 941,680. The business has a 50-day simple moving average of $218.46 and a two-hundred day simple moving average of $174.48. The firm has a market cap of $14.65 billion, a P/E ratio of 21.17, a price-to-earnings-growth ratio of 0.79 and a beta of 0.88. DaVita has a fifty-two week low of $101.00 and a fifty-two week high of $247.49.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on DVA. Truist Financial increased their price target on DaVita from $205.00 to $250.00 and gave the company a “hold” rating in a research note on Tuesday, July 14th. Deutsche Bank Aktiengesellschaft raised DaVita from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $126.00 to $220.00 in a research note on Wednesday, May 6th. TD Cowen raised their target price on DaVita from $144.00 to $201.00 and gave the company a “hold” rating in a research note on Monday, May 11th. UBS Group lifted their target price on DaVita from $235.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, July 10th. Finally, Zacks Research cut shares of DaVita from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Two investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $216.50.

Read Our Latest Stock Analysis on DaVita

Insider Buying and Selling

In related news, CFO Joel Ackerman sold 51,471 shares of the firm’s stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $192.10, for a total value of $9,887,579.10. Following the completion of the transaction, the chief financial officer owned 132,434 shares of the company’s stock, valued at approximately $25,440,571.40. This trade represents a 27.99% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Kathleen Alyce Waters sold 15,405 shares of the stock in a transaction on Monday, June 15th. The shares were sold at an average price of $208.40, for a total value of $3,210,402.00. Following the completion of the sale, the insider owned 109,194 shares of the company’s stock, valued at $22,756,029.60. The trade was a 12.36% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 1.90% of the company’s stock.

Hedge Funds Weigh In On DaVita

Institutional investors and hedge funds have recently bought and sold shares of the business. Invesco Ltd. lifted its position in shares of DaVita by 2.0% in the third quarter. Invesco Ltd. now owns 1,679,248 shares of the company’s stock worth $223,122,000 after purchasing an additional 32,358 shares in the last quarter. Morgan Stanley increased its stake in DaVita by 5.1% in the 4th quarter. Morgan Stanley now owns 1,477,045 shares of the company’s stock valued at $167,807,000 after buying an additional 71,156 shares during the period. Dimensional Fund Advisors LP increased its stake in DaVita by 0.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,089,100 shares of the company’s stock valued at $123,733,000 after buying an additional 3,507 shares during the period. Arrowstreet Capital Limited Partnership lifted its position in DaVita by 109.7% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 553,809 shares of the company’s stock worth $73,585,000 after buying an additional 289,725 shares in the last quarter. Finally, Corient Private Wealth LLC boosted its stake in shares of DaVita by 1,493.1% during the 4th quarter. Corient Private Wealth LLC now owns 358,299 shares of the company’s stock valued at $40,706,000 after buying an additional 335,809 shares during the period. Hedge funds and other institutional investors own 90.12% of the company’s stock.

About DaVita

(Get Free Report)

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.